|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
8/3/2011 9:54:12 AM
BOCA RATON, Fla., Aug. 3, 2011 (GLOBE NEWSWIRE) -- David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB:VCRT), today announced that Vicor and ZOLL Medical Corporation (Nasdaq:ZOLL) have entered into a licensing and development agreement. ZOLL Medical Corporation is the leading global manufacturer of resuscitation and critical care devices and related software solutions, including professional defibrillators and automated external defibrillators (AEDs), the LifeVest® Wearable Defibrillator, the AutoPulse® Non-invasive Cardiac Support Pump, and Intravascular Temperature Management (IVTM™) equipment. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing Vicor's patented, proprietary PD2i® nonlinear algorithm. Clinical use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i® nonlinear algorithm as a valid metric for risk stratifying specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), trauma victims for imminent death absent immediate lifesaving intervention, and ICU patients for mortality risk stratification.
|
|
|
|
|
|
|
|
|
|
|